Implementation of lipidomics in the clinical routine: can fluoride/citrate blood sampling tubes improve the preanalytical stability?



Lisa Hahnefeld¹, Robert Gurke^{1,2}, Dominique Thomas¹, Yannick Schreiber², Stephan M. G. Schäfer², Sandra Trautmann¹, Isabel F. Snodgrass^{1,2}, Daniel Kratz¹, Gerd Geisslinger^{1,2}, Nerea Ferreirós¹

¹ pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany

² Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Branch for Translational Medicine and Pharmacology TMP, Frankfurt am Main, Germany

Introduction


Lipid compounds are of great interest as potential biomarkers for several diseases. Discovering biomarkers is very challenging since their suitability must be validated, requiring not only robust analytical procedures but also ensuring the quality of the whole analytical process from sampling to data analysis. In particular, the impact of preanalytical sample handling on analyte stability is a rarely described but very important parameter in analyzing any endogenous compound. Especially endocannabinoids and lysophosphatidic acids (LPA) were reported to show rapid ex-vivo formation at room temperature [1,2]. In the case of endocannabinoids and related compounds, storage of whole blood samples on ice directly after sampling is still insufficient for stabilization [3]. Negligence of the preanalytical stability of LPA might have even led to their false reporting as potential biomarkers for ovarian cancer [4]. Therefore, the primary objective of the study was assessing the preanalytical stability of several lipid mediators in human whole blood and plasma samples under different sampling and storage conditions. Furthermore, commercially available sodium fluoride/citrate tubes (Sarstedt) were tested as a way to improve lipid stability, which could be easily implemented into the clinical routine.

Results


Endocannabinoids:

- Increased in K3EDTA whole blood in ice water
- additive


Relative change ± SD (%) after 20 minutes in ice water



oncentrations (mean ± SEM) after incubation of plasma or whole blood samples at RT or in ice water




Design of Experiment: Stability Study




Lysophosphatidic acids:

- Rapid ex-vivo formation both in whole
- blood and plasma at room temperature
- Stable for up to 4 hours in ice water
- NaF/citrate greatly improves LPA stability
- NaF/citrate blood/plasma stable at RT for up to 2 hours

Plasma concentrations (mean ± SEM) after incubation of plasma or whole blood samples at RT or in ice water





Non-targeted lipidomics:

Time-dependent increase of free fatty acids, diglycerides, LPC and LPE in plasma (>20% after 4 h) at RT

Fold changes after incubation of whole blood at RT 73 unequivocally identified lipids out of the 360 changed features in K3EDTA whole blood are shown, with a FDR < 0.1 (paired t-test) between 24 h of incubation time and control samples (a total of 3198 aligned features was processed, n = 10).

K3EDTA


Color Key 1 2 NaF/citrate Fold change to to

K3EDTA:

- Standard additive for lipid analysis
- Inhibits enzymes with divalent metal ions (Ca²⁺, Mg²⁺)
- Stability problems for endocannabinoids and LPA [1,2]

Sodium fluoride/citrate:

- Fluoride inhibits a broad range of enzymes,
 - including phosphate binding sites [5]
- Citrate binds Ca²⁺, preventing coagulation
- Acidification prevents isomerization of 2-AG to the biological inactive 1-AG [6]
- **LC-MS Methodology**



Endocannabinoids:


- Liquid-Liquid Extraction with ethylacetate and hexane
- 200 μL sample volume
- Agilent 1290 Infinity I UHPLC system
- Acquity UPLC BEH C18 column (100 x 2.1 mm, 1.7 μm)
- MRM on a Sciex QTrap 6500+, operated in positive ESI
- 1-/2-arachidonoyl glycerol (AG), anandamide (AEA), oleoylethanolamine/vaccenic acid ethanolamine (OEA/VEA)), palmitoylethanolamine (PEA)

Lysophosphatidic acids (LPA):

- Liquid-Liquid Extraction with n-butanol and Na₂HPO₄/citrate buffer
- Agilent 1200 HPLC system
- Luna C18 (2) column (50 x 2 mm, 5 μm)
- MRM on a Sciex QTrap 5500, operated in negative ESI LPA 16:0, 18:0, 18:1, 18:2, 18:3, 20:4

- Plasma processing at RT is acceptable for < 1 h
- Similar results for whole blood samples
- Whole blood samples should be kept in ice water
- NaF/citrate improves phospholipid stability both in whole blood and in plasma


Rel. concentration (%) in plasma after incubation at RT 120 storage time (- LPC 18:0 ED LPC O-16:1 EDT ---·LPC O-16:1 NaF



Different baseline levels in K3EDTA and NaF/citrate plasma

- Lowered baseline levels of many lipids were observed in NaF/citrate plasma
- Lipid classes were affected differently (very lipophilic) compounds decreased more)
- > Total protein conc. in NaF/citrate plasma was decreased by 11 %
- Decreased lipoprotein solubility in NaF/citrate?

Rel. concentration (%) in NaF+citrate / K3EDTA



100 μL sample volume

BPC (+) Cholesteryl ester, TG PC, PE, PI, PS, SM Ceramides, DG LPC, LPE, Cholestero 3.5 Retention time [min

Non-targeted lipidomics:

 \blacktriangleright Liquid-Liquid Extraction with MTBE with 20 µL sample volume Shimdazu Nexera-X2 UHPLC system

Zorbax Eclipse Plus RRHD column (50 x 2.1, 1.8 μm)

Screening from 100 - 1000 m/z (± 5 ppm mass error) & datadependent acquistion on a Sciex QTOF 6600, operated in negative and positive ESI

References

[1] A. Pastor, M. Farre, M. Fito, F. Fernandez-Aranda, R. de la Torre, Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs, J Lipid Res 55(5) (2014) 966-77.

[2] J.M. Onorato, P. Shipkova, A. Minnich, A.F. Aubry, J. Easter, A. Tymiak, Challenges in accurate quantitation of lysophosphatidic acids in human biofluids, J Lipid Res 55(8) (2014) 1784-96 [3] R. Gurke, D. Thomas, Y. Schreiber, S.M.G. Schäfer, S.C. Fleck, G. Geisslinger, N. Ferreirós, Determination of endocannabinoids and endocannabinoid-like substances in human K3EDTA plasma – LC-MS/MS method validation and pre-analytical characteristics, Talanta (2019)

[4] T. Yagi, M. Shoaib, C. Kuschner, M. Nishikimi, L.B. Becker, A.T. Lee, J. Kim, Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer, Cancers (Basel) 11(4) (2019).

[5] M. Chabre, Aluminofluoride and beryllofluoride complexes: new phosphate analogs in enzymology, Trends in Biochemical Sciences 15(1) (1990) 6-10.

- [6] C.A. Rouzer, K. Ghebreselasie, L.J. Marnett, Chemical stability of 2-arachidonylglycerol under biological conditions, Chemistry and Physics of Lipids 119(1) (2002) 69-82.
- [7] L.A. Ferreira, V.N. Uversky, B.Y. Zaslavsky, Effects of the Hofmeister series of sodium salts on the solvent properties of water, Physical Chemistry Chemical Physics 19(7) (2017) 5254-5261.

Conclusion

Preanalytical stability has to be considered before lipid biomarker searching!

- Endocannabinoid levels in K3EDTA blood were increased after 20 min in ice water
- Increased LPA levels in K3EDTA blood & plasma stored for 20 min at RT
- K3EDTA blood and plasma for lipidomics analysis can be stored for up to 4 h in ice water
- Chilled NaF/citrate blood can be stored for 1 h for endocannabinoid measurement
- NaF/citrate greatly improves phospholipid and endocannabinoid stability
- Baseline levels of several lipid (-mediators) differ between K3EDTA and NaF/citrate

We propose sodium fluoride/citrate as anticoagulant for endocannabinoid measurement!

